среда, 27 июля 2016 г.

United Therapeutics Corp. (UTHR) Upgraded to "Buy" by Zacks Investment Research

United Therapeutics Corp. (UTHR) Upgraded to "Buy" by Zacks Investment Research


The brokerage presently has a $126.00 target price on the biotechnology company's stock. Zacks Investment Research's price target would suggest a potential upside of 12.05% from the company's current price.



from Biotech News